Correspondence 0001493152-24-042469 from Invizyne Technologies Inc (IZTC) (CIK 0002010788) (EXOZ)
Invizyne Technologies Inc (IZTC) (CIK 0002010788)
Date: Oct. 25, 2024 · CIK: 0002010788 · Accession: 0001493152-24-042469
AI Filing Summary & Sentiment
File numbers found in text: 333-256803, 333-265967, 333-271113, 333-276987, 333-279893
Letter
United States Securities and Exchange Commission Division of Corporation Finance – Office of Attention: Mr. Tyler Howes Ms. Christine Torney Ms. Lynn Dicker Re: Invizyne Technologies Inc. (“Invizyne”) File No. 333-276987
Dear Mr. Howes:
Pursuant to our conversation this morning, here are five financings where there was a concurrent private placement, three of which were IPOs.
BioAge Labs, Inc.
IPO
September 25, 2024
Registration Nos. 281901 and 282334
https://www.sec.gov/Archives/edgar/data/1709941/000119312524226927/d835745d424b4.htm
Landbridge Company LLC
IPO
June 27, 2024
Registration Statement No. 333-279893
https://www.sec.gov/Archives/edgar/data/1995807/000119312524172433/d752700d424b4.htm
Clearsign Technologies Corp.
Secondary
April 19, 2024
Registration No. 333-265967
https://www.sec.gov/Archives/edgar/data/1434524/000110465924050203/0001104659-24-050203-index.html
LegalZoom.com, Inc.
IPO
June 29, 2021
Registration No. 333-256803
https://www.sec.gov/Archives/edgar/data/1286139/000119312521204774/d146270d424b4.htm
Safehold Inc.
Secondary
August 7, 2023
Registration No. 333-271113
https://www.sec.gov/Archives/edgar/data/1095651/000110465923089339/0001104659-23-089339-index.html
As mentioned in the telephone call, the one individual that is committed to the warrant purchase is a long term investor in MDB Capital transactions. He is an investor in MDB Capital Holdings LLC, so he is currently an indirect investor in Invizyne, through that limited liability company, which is treated as a partnership. This investor is making a substantial investment in the initial public offering of Invizyne. There is a possible second person that would be similarly situated. There are only two such persons that would participate in the private placement.
Please contact me for further information.
Sincerely,
/s/
Andrew D. Hudders
Show Raw Text
CORRESP
1
filename1.htm
Attorneys
at Law | 711 Third Ave., New York, NY 10017-4014
T
(212) 907-7300 | F (212) 754-0330 | www.golenbock.com
Direct
Dial No.: (212) 907-7349
Direct
Fax No.: (212) 754-0330
Email
Address: AHudders @GOLENBOCK.COM
October
25, 2024
United
States Securities and Exchange Commission
Division
of Corporation Finance – Office of
Life
Sciences
Washington,
DC 20549
Attention: Mr.
Tyler Howes
Ms.
Laura Crotty
Ms.
Christine Torney
Ms.
Lynn Dicker
Re:
Invizyne
Technologies Inc. (“Invizyne”)
File
No. 333-276987
Dear
Mr. Howes:
Pursuant
to our conversation this morning, here are five financings where there was a concurrent private placement, three
of which were IPOs.
BioAge
Labs, Inc.
IPO
September
25, 2024
Registration
Nos. 281901 and 282334
https://www.sec.gov/Archives/edgar/data/1709941/000119312524226927/d835745d424b4.htm
Landbridge
Company LLC
IPO
June
27, 2024
Registration
Statement No. 333-279893
https://www.sec.gov/Archives/edgar/data/1995807/000119312524172433/d752700d424b4.htm
Clearsign
Technologies Corp.
Secondary
April
19, 2024
Registration
No. 333-265967
https://www.sec.gov/Archives/edgar/data/1434524/000110465924050203/0001104659-24-050203-index.html
LegalZoom.com,
Inc.
IPO
June
29, 2021
Registration
No. 333-256803
https://www.sec.gov/Archives/edgar/data/1286139/000119312521204774/d146270d424b4.htm
Safehold
Inc.
Secondary
August
7, 2023
Registration
No. 333-271113
https://www.sec.gov/Archives/edgar/data/1095651/000110465923089339/0001104659-23-089339-index.html
As
mentioned in the telephone call, the one individual that is committed to the warrant purchase is a long term investor in MDB Capital
transactions. He is an investor in MDB Capital Holdings LLC, so he is currently an indirect investor in Invizyne, through that
limited liability company, which is treated as a partnership. This investor is making a substantial investment in the initial
public offering of Invizyne. There is a possible second person that would be similarly situated. There are only two such persons that
would participate in the private placement.
Please
contact me for further information.
Sincerely,
/s/
Andrew D. Hudders
Andrew
D. Hudders